NBY - מכפיל P/S עתידי NovaBay

לוגו תאגידי של חברת NovaBay (NBY)

NovaBay Pharmaceuticals is recruiting leading ophthalmologists to develop innovative vision care products. Management has optimized the governance structure to reduce costs and increase reporting transparency. However, a cash deficit and shrinking margins are forcing the company to deplete its reserves. The forward price-to-sales valuation trend reflects a current market overvaluation, with the metric settling at 18.50.

NovaBay Pharmaceuticals, Inc. - יחס מחיר להכנסות חזויות NBY (תקופה 04.07.2022 - 18.04.2026)

NBY (NovaBay): פילוחים אנליטיים ודוחות לפי אינדיקטורים

- מחיר מניה ומחיר יעד קונצנזוס:
ניתוח מסכם של החברה:NBY (NovaBay Pharmaceuticals)
מוצרים מיוצרים של NovaBay Pharmaceuticals Inc.

The forward P/S ratio assesses the market value of NovaBay Pharmaceuticals (NBY) relative to projected revenue, determining the extent of the premium paid for future cash flows. By analyzing the expected price-to-sales ratio at 18.50, an investor can evaluate the capitalization's resilience to the expansion of the Avenova brand across pharmacy chains and the efficiency of developing the high-margin direct-to-consumer (DTC) online sales segment.